Oxford Biomedica PLC

Regulatory Filings • Jun 7, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3755A

Oxford Biomedica PLC

07 June 2016

Establishment of a New Non-Exclusive LentiVector® Licence with MolMed

Oxford, UK - 7 June 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive licence under Oxford BioMedica's LentiVector® platform technology patents for manufacturing and development services with MolMed S.p.A ("MolMed") (MLM. MI). A previous retroviral patent agreement between Oxford BioMedica and MolMed has now expired.

John Dawson, CEO of Oxford BioMedica, commented: "This agreement with MolMed is a further endorsement of our dominant patent estate and of our unique LentiVector® platform technology for state-of-the-art bioprocessing and development services. Oxford BioMedica is already a partner for leading companies in the gene and cell therapy sector including Novartis, Sanofi, GSK and Immune Design."

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: +44 (0)20 3709 5700

Notes for editors

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAAKKEFSKEAF